CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts

CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026. Kulkarni said the company’s strategy rests on several layers of potential value: the commercial launch of CASGEVY, three later-stage assets that could be positioned for pivotal studies next year, early clinical programs, and research efforts in areas including in vivo cell editing. CASGEVY, which CRISPR Therapeutics markets with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia, recently received an FDA label expansion for patients ages 2 years and older. Kulkarni described the pediatric indication as a “great tailwind,” citing Vertex’s most recently disclosed quarterly CASGEVY revenue of approximately $76 million and more than 100 patient initiations per quarter. He said the pediatric population could support additional treatment starts because more children’s hospitals have experience with the required procedures and because earlier intervention may help patients avoid disease-related organ damage. According to Kulkarni, many initial launch bottlenecks—including reimbursement processes, hospital contracting and manufacturing capacity—have largely been addressed. However, the treatment journey can still take six to nine months or longer from initiation to treatment. He said delays are not primarily related to manufacturing, but can reflect exchange transfusions before cell collection and patient scheduling needs. Kulkarni also pointed to potential gentler conditioning regimens as a future growth driver. He said a regimen that could reduce hospital stays to roughly three days or less, compared with two or three weeks, could broaden access among more moderate patients. He added that CRISPR Therapeutics is pursuing in vivo hematopoietic stem cell editing, which he said could ultimately expand treatment beyond the current markets in the U.S. and Western Europe. The company expects to report Phase 1b data for CTX310 in severe hypertriglyceridemia by year-end. CTX310 is designed as a one-time CRISPR-Cas9 treatment targeting ANGPTL3, a protein associated with lipid metabolism and cardiovascular risk. Kulkarni said data presented at the European Society of Cardiology meeting showed reductions of up to 80% in ANGPTL3 at higher dose levels, along with reductions of nearly 50% in LDL cholesterol and triglycerides in a mixed Phase 1a population. He said the company observed that ANGPTL3 reductions remained at approximately 80% one year after treatment in the data presented. The Phase 1b study is evaluating more defined ...